Good Afternoon Fellow Investors,
The news out this morning that Dynamic Response Group’s healthcare subsidiary, Medico Express, has received its provider number from Medicare has already pushed the company stock price up by more than 24%!
Read the DRG press release here.
Didn’t we tell you this would happen?
In our opinion, DRGZ is going to pop significantly higher as investors digest what this development means for the company.
Valued subscribers, we’ve committed to you from day one that we would provide alerts only on companies that we believe in 100%.
Since we issued our Monster Pick Alert on DRG back on July 13, the share price increased more than five fold, and with today’s news, it is rocketing skyward once again.
If you already have a position in DRGZ, hold on for the ride! If you’re thinking of investing, look at the fundamentals. This is not your typical micro-cap stock!
Simply put, DRG’s horizons have instantaneously been expanded by leaps and bounds.
Last year, the company generated revenues of more than $40 million selling basic household products.
Consider how high its numbers will climb as it begins rolling out high-demand medical products that save lives and dramatically improve the quality of life for people with serious medical conditions.
Here are additional key points you need to know about DRG.
* With the acquisition of its Medicare provider number, the company has earned the right to market Medicare-eligible medical products in 45 states, and it is adding more states all the time. No other direct-response company is doing this!
* As a direct-to-consumer marketing specialist, it is ideally equipped to target specific medical-market niches, create loyal customer followings and generate high levels of repeat orders.
* Medico’s direct-to-consumer marketing model will provide a tangible benefit to Medicare consumers because it will make it easier for them to obtain the products the need.
* Medico’s initial strategy will be to target the American Hispanic community with diabetic-related products. This narrow market segment alone is estimated to be worth a billion dollars annually in product sales.
*
In anticipation of receiving its subscriber number, DRG has already prepared a Spanish-language infomercial campaign and is beginning running ads today! The ads are appearing on CNN Español, MEGA TV, Univision and Telefutura.
* Down the road, DRG intends to broaden its focus to encompass all different consumer groups and the full range of Medicare-eligible medical products.
It is not an exaggeration to say the potential for revenue growth at DRG is absolutely staggering.
At the same time, DRG will continue to develop, refurbish and market consumer products such as the electronic pest-control system Riddex Plus.
Last month, DRG announced that its sales of Riddex Plus have surpassed the $40 million mark, which, in our opinion, is simply amazing.
In doing our due diligence on DRG before we issued our alert, we were initially attracted to the company based on the performance of its consumer products division. Then we learned about its pursuit of a Medicare provider number, and we realized that this company could achieve extraordinary growth.
Now that growth is about to happen in an explosive way!
In our opinion, investors should consider DRGZ for their long-term portfolios. Based on our research, we believe there is no reason why DRGZ could not trade as high as $5.00 per.
We repeat, in our view, DRG at its current price is substantially undervalued.
Keep an eye on your inbox for more coverage on DRGZ.
We’ll also have more news for you very soon about our NEXT MONSTER PICK ALERT!
Remember, SMALL is the new BIG!
STAY TUNED!
Sincerely,
The FreeInvestmentReport.com Team
Disclaimer
The disclaimer is to be read and fully understood before using our site or joining our email list.
PLEASE NOTE WELL: The employees of FreeInvestmentReport.com (?the Company?) are not registered as investment advisors in any jurisdiction whatsoever. Full disclaimer can be read here.
Release of Liability: Through use of this website, viewing or using any of the information, you agree to hold the Company, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data.
Please be advised that the Company is often compensated for issuing press releases, profiles or opinions concerning particular companies. Its opinion is, therefore, not unbiased, and you should consider this factor when evaluating the Company`s statements regarding a company. The Company`s officers and directors reserve the right to buy additional shares of the company discussed in this opinion and may profit in the event those shares rise in value. When the Company receives free trading shares as compensation for a profiled company, the Company may sell part or all of any such shares during the period in which the Company is performing such services. The Company will also disclose any compensation. The Company has received 400,000 free trading shares from a third party as compensation and expects to receive additional compensation in the future.
Any opinions expressed are subject to change without notice. The Company encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled or is available from public sources; the Company makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Neither the Company nor any of its affiliates are registered investment advisors or broker dealers.